Sanara MedTech earnings release, May 11, 2026

Sanara MedTech Inc. (SMTI) · Form 8-K, Item 2.02 · Filed · SEC filing

Exhibit

99.1

Sanara

MedTech Inc. Reports First Quarter 2026 Financial Results (Unaudited)

Net

Revenue Growth of 19% and Net Profitability from Continuing Operations of $0.04 Per Fully Diluted Share for the Quarter

FORT

WORTH, TX, May

11,

2026 (GLOBE NEWSWIRE) — Sanara MedTech Inc. (“Sanara,” “Sanara MedTech,” the

“Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, today reported its financial results for the first quarter ended March 31, 2026.

First

Quarter 2026 Financial Summary

(1)

(1)

As a result of the Company’s strategic realignment, the operations of Tissue Health Plus (“THP”), which were previously reported as the THP segment, have been classified as discontinued operations in Sanara’s financial statements for the three months ended March 31, 2026 and 2025.

(2)

Adjusted EBITDA is a non-GAAP financial measure. See the discussion and the reconciliation at the end of this release for additional information.

Management

Comments

Seth

Yon, President and Chief Executive Officer of Sanara, commented, “The first quarter of 2026 is the first full quarter in which the Company was entirely focused on the surgical market, and the results reflected strong execution. We delivered net revenue growth of 19% and gross margin improvement, and achieved GAAP net profitability, a reflection of the strength of our sharpened focus and enhanced financial model. We’re particularly encouraged by these results given that the first quarter is historically our slowest sales period of the year and was also impacted by a three-day shipping interruption in January due to a weather-related shut down.

“During the end of 2025 and continuing into 2026, we began strengthening our sales team in an effort to support enhanced net revenue growth and our heightened focus on the surgical setting, expanding the sales team to reach a total of 43 reps,” Mr. Yon stated. “Additionally, we experienced meaningful growth in our surgeon users in the first quarter of 2026 as compared to the first quarter of 2025, and, as of quarter end, our products were contracted or approved to be sold in over 4,000 hospitals and ambulatory surgery centers throughout the United States, our products were sold in over 1,400 facilities throughout the United States, and we had agreements with more than

450 distributors.

“Looking ahead, we believe we are well positioned with our strengthened sales team and refined, pure play focus on the surgical operating setting to drive enhanced results. From a capital allocation perspective, this means tightening our scope and strategically investing in R&D to grow our pipeline and introduce new products to the market. With our visibility today, we remain confident in our full-year guidance of 13% to 17% net revenue growth,” Mr. Yon concluded.

First

Quarter of 2026 Revenue

The following table summarizes revenue streams from product sales for the three months ended March 31, 2026 and 2025:

First

Quarter of 2026 Financial Results

(1)

Net revenue for the first quarter of 2026 was $27.8 million, compared to $23.4 million for the first quarter of 2025, an increase of $4.4 million, or 19%, year-over-year. The increase in net revenue was driven by an increase of $4.4 million, or 21%, in sales of soft tissue repair products, offset by a slight decrease of

$46,067, or 2%, in sales of bone fusion products. The increase in net revenue is primarily due to increased sales of soft tissue repair products, including CellerateRX®

Surgical Powder and

BIASURGE®

Advanced Surgical Solution, supported by increased market penetration and geographic expansion, and the Company’s strategy to continue expanding and developing its independent distribution network in both new and existing U.S. markets.

Gross profit for the first quarter of 2026 was $25.9 million, compared to $21.6 million for the first quarter of 2025, an increase of $4.3 million, or 20%, year-over-year. Gross margin was 93% of net revenue for the first quarter of 2026, compared to 92% of net revenue for the first quarter of 2025. The increase in gross profit and higher gross margin realized in the first quarter of 2026 was primarily due to the net revenue growth factors above and product mix.

Operating expenses for the first quarter of 2026 were $23.2 million, or 83.6% of sales, compared to $20.8 million, or 88.6% of sales, for the first quarter of 2025, an increase of $2.5 million, or 12%, year-over-year. The increase in operating expenses was primarily due to higher selling, general, and administrative expenses

(“SG&A”) offset by lower research and development expenses

(“R&D”), for the first quarter of

2026. Higher SG&A is related to increased direct sales and marketing expenses, which accounted for approximately $1.9 million of the increase, approximately $0.5 million in increase related to compensation expense and approximately $0.2 million in increase related to contracted services and warehousing and distribution costs.

R&D for the first quarter of 2026 decreased to $0.8 million, or 2.7% of sales, compared to R&D of $1.0 million, or 4.1% of sales, for the first quarter of 2025. While R&D will fluctuate from quarter to quarter based on timing of projects, the Company expects R&D, on an annual basis, to be in the range of 5% to 7% of sales.

Operating income for the first quarter of 2026 was $2.6 million, compared to operating income of $0.8 million for the first quarter of 2025.

Other expense for the first quarter of 2026 was $2.2 million, compared to $1.4 million for the first quarter of 2025. The increase in other expense was primarily due to higher interest expense and fees related to the Company’s term loan with CRG Servicing LLC and the... (truncated)losses from equity method investments.

Net income from continuing operations for the first quarter of 2026 was $0.4 million, or $0.04 per diluted share, compared to a net loss from continuing operations of $0.6 million, or $0.07 per diluted share, for the first quarter of 2025. Net income from discontinued operations for the first quarter of 2026 was $0.1 million, compared to a net loss from discontinued operations of $2.9 million for the first quarter of 2025.

Adjusted

EBITDA

Financial statements

Income Statement

Three Months Ended March 31, — The following table summarizes revenue streams from product sales for the three months ended March 31, 2026 and 2025:

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Soft tissue repair products24,942,94520,532,440
Bone fusion products2,855,5892,901,656
Total Net Revenue27,798,53423,434,096

Income Statement

Three Months Ended March 31, — CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Net Revenue27,798,53423,434,096
Cost of goods sold1,923,5891,834,967
Gross profit25,874,94521,599,129
Operating expensesSelling, general and administrative21,881,52019,129,208
Operating expensesResearch and development759,592950,359
Operating expensesDepreciation and amortization587,252694,032
Operating expensesTotal operating expenses23,228,36420,773,599
Operating expensesOperating income2,646,581825,530
Other income (expense)Interest expense-1,799,345-1,317,092
Other income (expense)Share of losses from equity method investments-462,507-143,608
Other income (expense)Interest income12,9583,672
Other income (expense)Gain on disposal of property and equipment10,932
Other income (expense)Total other income (expense)-2,248,894-1,446,096
Other income (expense)Net income (loss) from continuing operations397,687-620,566
Other income (expense)Net income (loss) from discontinued operations60,916-2,906,817
Other income (expense)Net income (loss)458,603-3,527,383
Other income (expense)Less: Net loss attributable to noncontrolling interest from continuing operations-354-206
Other income (expense)Net income (loss) attributable to Sanara MedTech shareholders458,957-3,527,177
Net income (loss) per share, basic:Continuing operations0.04-0.07
Net income (loss) per share, basic:Discontinued operations0.01-0.34
Net income (loss) per share, basic:Net income (loss) per share of common stock, basic0.05-0.41
Net income (loss) per share, diluted:Continuing operations0.04-0.07
Net income (loss) per share, diluted:Discontinued operations0.01-0.34
Net income (loss) per share, diluted:Net income (loss) per share of common stock, diluted0.05-0.41
Net income (loss) per share, diluted:Weighted average number of common shares outstanding, basic8,706,6788,570,104
Net income (loss) per share, diluted:Weighted average number of common shares outstanding, diluted8,985,8668,570,104

Income Statement

Three Months Ended March 31,

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Numerator:Net income (loss) from continuing operations397,687-620,566
Numerator:Net income (loss) from discontinued operations60,916-2,906,817
Numerator:Less: Net loss attributable to noncontrolling interests from continuing operations-354-206
Numerator:Net income (loss) attributable to Sanara MedTech shareholders458,957-3,527,177
Denominator:Weighted average shares, basic8,706,6788,570,104
Denominator:Dilutive effect of stock options10,218
Denominator:Dilutive effect of unvested shares268,970
Denominator:Weighted average shares, diluted8,985,8668,570,104

Income Statement

Three Months Ended March 31, — Reconciliation of Net income (loss) from continuing operations to Adjusted EBITDA:

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Net income (loss) from continuing operations397,687-620,566
Adjustments:Interest expense1,799,3451,317,092
Adjustments:Depreciation and amortization(1)587,252694,032
Adjustments:Noncash share-based compensation1,028,3351,175,496
Adjustments:Share of losses from equity method investments462,507143,608
Adjustments:Gain on disposal of property and equipment-10,932
Adjustments:Interest income-12,958-3,672
Adjustments:Adjusted EBITDA4,262,1682,695,058

Income Statement

2025 – Q12025 – Q22025 – Q32025 – Q42025 – TOTAL2024 – Q12024 – Q22024 – Q32024 – Q42024 – TOTAL2023 – Q12023 – Q22023 – Q32023 – Q42023 – TOTAL
Net Revenue23,434,09625,804,25226,333,81927,545,815103,117,98218,536,63820,158,82321,671,59926,305,36586,672,42515,519,18715,753,16416,024,94817,689,81364,987,112
Cost of goods sold1,834,9671,937,2821,874,2141,874,5067,520,9691,890,0462,008,6861,991,9872,249,1828,139,9012,116,6942,187,5161,751,3491,788,1627,843,721
Gross profit21,599,12923,866,97024,459,60525,671,30995,597,01316,646,59218,150,13719,679,61224,056,18378,532,52413,402,49313,565,64814,273,59915,901,65157,143,391
Operating expensesSelling, general and administrative(1)19,129,20819,634,31919,877,87520,075,59778,716,99915,683,03918,349,92417,420,34720,220,33271,673,64212,467,39513,301,23013,460,40415,597,82354,826,852
Operating expensesResearch and development950,3591,056,7961,029,5912,035,7375,072,483578,981582,443783,840883,3992,828,663235,236208,727225,886232,933902,782
Operating expensesDepreciation and amortization(2)694,032688,546610,899668,3962,661,873698,502698,407696,888692,0322,785,829372,020396,597590,563687,6792,046,859
Operating expensesChange in fair value of earnout liabilities-103,78189,330-14,451-191,127-436,004-758,78387,578-1,298,336
Operating expensesAsset impairment charges1,841,1201,841,120

Income Statement

Reconciliation of Net income (loss) from continuing operations to Adjusted EBITDA (Unaudited):

2025 – Q12025 – Q22025 – Q32025 – Q42025 – TOTAL2024 – Q12024 – Q22024 – Q32024 – Q42024 – TOTAL2023 – Q12023 – Q22023 – Q32023 – Q42023 – TOTAL
Net income (loss) from continuing operations-620,566500,259834,493-1,107,310-393,124-477,485-2,214,313-180,488934,703-1,937,583518,96395,098567,235-740,811440,485
Adjustments:Interest expense1,317,0921,791,5681,818,1051,833,0356,759,800267,336644,346927,5771,289,1363,128,3956188,294287,483475,783
Adjustments:Depreciation and amortization(1)694,032688,546610,899668,3962,661,873698,502698,407696,888692,0322,785,829372,020396,597590,563687,6792,046,859
Adjustments:Noncash share-based compensation1,175,4961,278,8711,164,0701,155,5454,773,982753,6161,046,3211,003,5991,165,4723,969,008545,2141,064,516813,606777,9943,201,330
Adjustments:Change in fair value of earnout liabilities-103,78189,330-14,451-191,127-436,004-758,78387,578-1,298,336
Adjustments:Asset impairment charges1,841,1201,841,120
Adjustments:Share of losses from equity method investments143,608195,482288,642324,734952,46631,44858,55990,007
Adjustments:Gain on disposal of property and equipment-10,932-10,932
Adjustments:Interest income-3,672-3,672-21,978-21,978
Adjustments:Executive separation costs(2)260,275172,048432,323904,78159,685964,466
Adjustments:Acquisition costs (3)4,82620,000-24,826225,08924,812-64,872185,029423,513423,513
Adjustments:Adjusted EBITDA2,695,0584,719,8274,908,2574,690,69417,013,8361,138,1881,393,9612,563,5214,053,0529,148,7221,245,0761,120,2071,400,9151,523,4365,289,634

Balance Sheet

March 31, 2026 — CONSOLIDATED BALANCE SHEETS

March 31, 2026 – (Unaudited)December 31, 2025
Current assetsCash13,594,45916,578,857
Current assetsAccounts receivable, net13,617,40711,998,075
Current assetsInventory, net3,120,7953,948,748
Current assetsPrepaid and other assets816,788948,620
Current assetsCurrent assets related to discontinued operations48,53367,863
Current assetsTotal current assets31,197,98233,542,163
Long-term assetsIntangible assets, net17,860,27318,640,673
Long-term assetsGoodwill3,601,7813,601,781
Long-term assetsInvestment in equity securities14,164,35114,626,858
Long-term assetsRight of use assets – operating leases1,993,8502,075,634
Long-term assetsProperty and equipment, net458,880456,962
Long-term assetsTotal long-term assets38,079,13539,401,908
Long-term assetsTotal assets69,277,11772,944,071
Current liabilitiesAccounts payable905,3962,338,761
Current liabilitiesAccounts payable – related parties15,847
Current liabilitiesAccrued bonuses and commissions9,082,59611,781,435
Current liabilitiesAccrued royalties and expenses2,615,7982,684,626
Current liabilitiesEarnout liabilities – current235,001
Current liabilitiesOperating lease liabilities – current367,945353,229
Current liabilitiesCurrent liabilities related to discontinued operations713,2601,233,478
Current liabilitiesTotal current liabilities13,700,84218,626,530
Long-term liabilitiesLong-term debt46,226,42245,970,937
Long-term liabilitiesOperating lease liabilities – long-term1,770,7561,868,703
Long-term liabilitiesOther long-term liabilities559,602548,125
Long-term liabilitiesTotal long-term liabilities48,556,78048,387,765
Long-term liabilitiesTotal liabilities62,257,62267,014,295

Cash Flow

Three Months Ended March 31, — CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Cash flows from operating activities:Net income (loss)458,603-3,527,383
Adjustments to reconcile net income (loss) to net cash used in operating activities:Depreciation and amortization587,2521,124,410
Adjustments to reconcile net income (loss) to net cash used in operating activities:Gain on disposal of property and equipment-9,674
Adjustments to reconcile net income (loss) to net cash used in operating activities:Credit loss expense75,000179,034
Adjustments to reconcile net income (loss) to net cash used in operating activities:Inventory obsolescence62,800199,278
Adjustments to reconcile net income (loss) to net cash used in operating activities:Share-based compensation1,028,3351,304,904
Adjustments to reconcile net income (loss) to net cash used in operating activities:Noncash lease expense81,784274,055
Adjustments to reconcile net income (loss) to net cash used in operating activities:Share of losses from equity method investments462,507143,608
Adjustments to reconcile net income (loss) to net cash used in operating activities:Back-end fee181,944176,079
Adjustments to reconcile net income (loss) to net cash used in operating activities:Paid-in-kind interest411,324
Adjustments to reconcile net income (loss) to net cash used in operating activities:Accretion of finance liabilities27,11343,630
Adjustments to reconcile net income (loss) to net cash used in operating activities:Amortization and write-off of debt issuance costs73,54159,280
Changes in operating assets and liabilities:Accounts receivable, net-1,709,332368,284
Changes in operating assets and liabilities:Accounts receivable – related parties-2,254
Changes in operating assets and liabilities:Inventory, net765,153-605,628
Changes in operating assets and liabilities:Prepaid and other assets166,16232,759
Changes in operating assets and liabilities:Accounts payable-1,433,365595,836
Changes in operating assets and liabilities:Accounts payable – related parties15,84710,892
Changes in operating assets and liabilities:Accrued royalties and expenses-105,44267,224
Changes in operating assets and liabilities:Accrued bonuses and commissions-3,120,078-2,566,461
Changes in operating assets and liabilities:Operating lease liabilities-83,231-278,081
Changes in operating assets and liabilities:Net cash used in operating activities-2,465,407-1,998,884
Cash flows from investing activities:Purchases of property and equipment-43,772-1,722,649
Cash flows from investing activities:Proceeds from disposal of property and equipment60,000
Cash flows from investing activities:Investment in equity securities-3,517,206
Cash flows from investing activities:Net cash used in investing activities-43,772-5,179,855
Cash flows from financing activities:Loan proceeds, net of debt issuance costs of zero in 2026 and $183,750 in 202512,066,250
Cash flows from financing activities:Net settlement of equity-based awards-397,219
Cash flows from financing activities:Cash payment of finance and earnout liabilities-78,000-78,000
Cash flows from financing activities:Net cash provided by (used in) financing activities-475,21911,988,250
Cash flows from financing activities:Net increase (decrease) in cash-2,984,3984,809,511
Cash flows from financing activities:Cash, beginning of period16,578,85715,878,295
Cash flows from financing activities:Cash, end of period13,594,45920,687,806
Cash paid during the period for:Interest1,516,747626,779
Cash paid during the period for:Taxes14352,984
Supplemental noncash investing and financing activities:Non-monetary exchange to acquire intangible assets$-2,084,278
Supplemental noncash investing and financing activities:Conversion of note receivable into equity method investment1,101,478
Full release

(2) for the first quarter of 2026 was $4.3 million, compared to $2.7 million for the first quarter of 2025, an increase of $1.6 million, or 58%, year-over-year. Higher Adjusted EBITDA in the first quarter of 2026 was primarily due to net revenue growth offset by increases in SG&A.

Net cash used in operating activities in the first quarter of 2026 was $2.5 million, compared to $2.0 million of net cash used in operating activities in the first quarter of 2025. The increase in cash used in operating activities during the first quarter of 2026 was primarily due to the timing of commissions payments, higher cash interest expense resulting from a larger outstanding debt balance compared to the prior-year period and the absence of paid-in-kind interest.

As of March 31, 2026, the Company had $13.6 million of cash and $46.2 million of long-term debt, compared to $16.6 million and $46.0 million, respectively, as of December 31, 2025.

(1)

As a result of the Company’s strategic realignment, the operations of THP, which were previously reported as the THP segment, have been classified as discontinued operations in Sanara’s financial statements for the three months ended March 31, 2026 and 2025.

(2)

Adjusted EBITDA is a non-GAAP financial measure. See the discussion and the reconciliation at the end of this release for additional information.

Second

Quarter and

Full Year 2026 Financial Guidance

For the second quarter of 2026, Sanara expects net revenue to range from $28.5 million to $29.5 million, representing growth of approximately

10% to 14%, compared to net revenue of $25.8 million for the second quarter of 2025.

The

Company is reaffirming financial guidance for the full year ending December 31, 2026.

Sanara continues to expect full year 2026 net revenue to range from $116 million to $121 million, representing growth of approximately 13% to

17%, compared to net revenue of $103.1 million for the full year 2025.

Conference

Call

The

Company will host a conference call on Tuesday, May 12, 2026 at 8:00 a.m. Eastern Time to discuss the results of the quarter ended March 31, 2026 and hold a question and answer session at the end of the call. The toll-free number to call for this teleconference is 888-506-0062

(international callers: 973-528-0011) and the access code is 931324. A telephonic replay of the conference call will be available through

Tuesday, May 26, 2026, by dialing 877-481-4010 (international callers: 919-882-2331) and entering the replay passcode: 53818.

A live webcast of Sanara’s conference call is accessible by clicking here and will be made available under the “Events” section of the Company’s Investor Relations website, https://ir.sanaramedtech.com/. An online replay will be available for approximately one year following the conclusion of the live broadcast.

About

Sanara MedTech Inc.

Sanara

MedTech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. The Company develops, markets and distributes surgical products for use by physicians and clinicians in hospitals. Each of the Company’s products and technologies are designed to achieve the goal of providing better clinical outcomes at a lower overall cost for healthcare systems. Sanara’s products are primarily sold in the

North American surgical tissue repair market. Sanara markets and distributes CellerateRX®

Surgical Activated Collagen

Powder, BIASURGE®

Advanced Surgical Solution, FORTIFY TRG®

Tissue Repair Graft and FORTIFY FLOWABLE®

Extracellular Matrix, as well as a portfolio of advanced biologic products including: ACTIGEN®

Verified Inductive Bone

Matrix, ALLOCYTE®

Plus Advanced Viable Bone Matrix, BiFORM®

Bioactive Moldable Matrix and TEXAGEN®

Amniotic Membrane Allograft to the surgical market. The Company believes it can drive its pipeline from concept to preclinical and clinical development while meeting quality and regulatory requirements. The Company strives to be one of the most innovative and comprehensive providers of effective surgical solutions and is continually seeking to expand its offerings for patients requiring treatments in the

United States. For more information, please visit

SanaraMedTech.com.

Information about Forward-Looking Statements

The statements in this press release that do not constitute historical facts are “forward-looking statements,” within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. These statements may be identified by terms such as “aims,” “anticipates,” “believes,” contemplates,” “continue,”

“could,” “estimates,” “expects,” “forecast,” “guidance,” “intends,”

“may,” “plans,” “possible,” “potential,” “predicts,” “preliminary,”

“projects,” “seeks,” “should,” “targets,” “will” or “would,” or the negatives of these terms, variations of these terms or other similar expressions. These forward-looking statements include, among others, statements regarding the Company’s expected net revenue, the Company’s ability to achieve enhanced results by focusing on the surgical market, the Company’s business strategy and mission, the development of new products, the timing of commercialization of the Company’s products, and the regulatory approval process. These items involve... (truncated)ies associated with the development and process for obtaining regulatory approval for new products, the extent of product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, uncertainties associated with the development and process for obtaining regulatory approval for new products, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company’s most recent annual report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission, which could cause the Company’s actual operating results, performance or business plans or prospects to differ materially from those expressed in or implied by these statements.

All forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to revise any of these statements to reflect future circumstances or the occurrence of unanticipated events, except as required by applicable securities laws.

Investor

Relations Contact:

Walter

Frank or John Nesbett

IMS

Investor Relations

IR@sanaramedtech.com

(203)

972-9200

SANARA

MEDTECH INC. AND SUBSIDIARIES

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Sanara MedTech earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.